Results 281 to 290 of about 922,724 (383)
Pomalidomide enhances CD8<sup>+</sup> T and NK cell mediated killing of HIV-infected cells. [PDF]
Pascoe RD +12 more
europepmc +1 more source
A. Kamphorst +18 more
semanticscholar +1 more source
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source
KIAA1429 impairs anti-tumor immunity via regulation of PD-L1 and CD8<sup>+</sup> T cells in colorectal cancer. [PDF]
Du Y, Liu Y, Wang M, Wang Y, Lin M.
europepmc +1 more source
CircLRBA is highly expressed in breast cancer (BC) and associated with poor overall survival. Zeb1 mediated circLRBA facilitates BC cell proliferation, invasion, docetaxel (DTX) resistance and inhibits the infiltration of CD8+ T cell. CircLRBA could combine with SPOP to suppress the Twist1 ubiquitination degradation and enhances PD‐L1 transcription ...
Xiaosong Wang +8 more
wiley +1 more source
CD8 T cells are dispensable for experimental autoimmune prostatitis induction and chronic pelvic pain development [PDF]
Florencia C. Salazar +8 more
openalex +1 more source
TREM2 recognizes NETs‐derived MPO to promote DC maturation and antigen presentation, thereby exacerbating the autoimmune response in SLE. Mechanistically, TREM2 activation triggers the DAP12/SYK/ERK cascade and enhances NETs internalization by DCs, which in turn activates the cGAS/STING signaling pathway.
Jingxian Shu +7 more
wiley +1 more source
Dual blockades of TIM-3 and PD-1 effectively prevent hyper-progression and enhance the efficacy of anti-PD-1 therapy in high-grade serous ovarian cancer. [PDF]
Li J +9 more
europepmc +1 more source
E. Sato +17 more
semanticscholar +1 more source

